These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 37046631)

  • 1. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
    Queiroz MM; Lima NF; Biachi de Castria T
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

  • 4. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
    Lo JH; Agarwal R; Goff LW; Heumann TR
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary tract cancer prognostic and predictive genomics.
    Mondaca S; Nervi B; Pinto M; Abou-Alfa GK
    Chin Clin Oncol; 2019 Aug; 8(4):42. PubMed ID: 31431036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
    Weinberg BA; Xiu J; Lindberg MR; Shields AF; Hwang JJ; Poorman K; Salem ME; Pishvaian MJ; Holcombe RF; Marshall JL; Morse MA
    J Gastrointest Oncol; 2019 Aug; 10(4):652-662. PubMed ID: 31392046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
    Kang S; El-Rayes BF; Akce M
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 16. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
    Wilbur HC; Azad NS
    Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary tract cancers: current knowledge, clinical candidates and future challenges.
    Tariq NU; McNamara MG; Valle JW
    Cancer Manag Res; 2019; 11():2623-2642. PubMed ID: 31015767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current biologics for treatment of biliary tract cancers.
    Zhao DY; Lim KH
    J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs).
    Han S; Lee SY; Wang WW; Tan YB; Sim RHZ; Cheong R; Tan C; Hopkins R; Connolly J; Shuen WH; Toh HC
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.